GlassScriptPhysician profile
Saradasri K Wellikoff
NPI 1982090270
$2,751.15
in general payments reported to CMS, 2019-2025
21 companies · $953 in 2025
The $953 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $83.05 · 2022: $157 · 2023: $517 · 2024: $1,041 · 2025: $953.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,511.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,510.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $738.96 | 2023-2025 | Trodelvy |
| E.R. Squibb & Sons, L.L.C. | $401.17 | 2022-2025 | Opdivo, Opdualag |
| Merck Sharp & Dohme LLC | $372.37 | 2023-2025 | Keytruda, Welireg, Lynparza |
| Janssen Biotech, INC. | $302.08 | 2023-2025 | Darzalex, Tecvayli, Talvey |
| Lilly USA, LLC | $230.14 | 2023-2025 | Jaypirca, Verzenio |
| Pfizer INC. | $176.09 | 2023-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $81.77 | 2024-2025 | Ninlaro, Iclusig |
| Astellas Pharma US INC | $73.86 | 2025 | Vyloy |
| Abbvie INC. | $53.16 | 2024 | |
| Novocure INC. | $51.65 | 2021 | |
| Beigene USA, INC. | $47.19 | 2022-2025 | Brukinsa |
| Pharmaessentia USA Corporation | $39.69 | 2024-2025 | Besremi |
| Celgene Corporation | $38.70 | 2023 | Opdualag |
| Glaxosmithkline, LLC. | $26.78 | 2025 | Jemperli, Zejula |
| Caris Mpi, INC. | $24.73 | 2025 | Mi Cancer Seek |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kyowa Kirin, INC. | $24.37 | 2025 | |
| Amgen INC. | $19.28 | 2022 | |
| Novartis Pharmaceuticals Corporation | $17.76 | 2023 | |
| Adc Therapeutics America, INC. | $16.05 | 2021 | |
| Genzyme Corporation | $15.35 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Saradasri Wellikoff listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.